Evidence map›Paper›PMID 26132079›Full record

Trial reportPloS one2015

CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study.

Bénédicte M J Merle, Florence Richard, Pascale Benlian, Nathalie Puche, Cécile Delcourt, Eric H Souied

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 5 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 5 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Dyslipidemia in retinal metabolic disorders.EMBO molecular medicine · 2019
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Bénédicte M J MerleOphthalmology Department, Hôpital Intercommunal de Créteil, University Paris Est Créteil, Créteil, France.
Florence RichardUniversité de Lille Nord de France, INSERM774 Institut Pasteur de Lille, Lille, France; Université de Lille Nord de France, Lille, France.
Pascale BenlianCHRU de Lille, Lille, France; APHP - Saint-Antoine Hospital, Endocrinology and Metabolic Disease Department, F75012 Paris, France; Lille 2 University, School of Medicine, Department of Biochemistry and Molecular Biology, F-59045 Lille, France.
Nathalie PucheOphthalmology Department, Hôpital Intercommunal de Créteil, University Paris Est Créteil, Créteil, France.
Cécile DelcourtINSERM, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France; Univ. Bordeaux, ISPED, F-33000 Bordeaux, France.
Eric H SouiedOphthalmology Department, Hôpital Intercommunal de Créteil, University Paris Est Créteil, Créteil, France.
Hôpital Intercommunal de Créteil · FRHôpital Saint-Antoine · FRInserm · FRUniversité de Lille · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).

methodsThe Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.

resultsPatients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).

conclusionsThese results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.

trial registrationISRCTN registry 98246501.

Indexed as

Polymorphism, Single NucleotideAgedComplement Factor HDietary SupplementsDocosahexaenoic AcidsFemaleHumansMacular DegenerationMaleMiddle AgedProteinsARMS2 protein, humanComplement Factor HDocosahexaenoic AcidsProteins

Identifiers

PMID26132079
PMCPMC4489493
OpenAlexW799154883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.